◎CROとバイオ医薬品業界の戦略提携の現状のリポート発表

パレクセル・インターナショナル

2013/4/23 09:25

◎CROとバイオ医薬品業界の戦略提携の現状のリポート発表

AsiaNet 52787

共同JBN 0453 (2013.4.23)

【ボストン2013年4月22日】有力な世界的バイオ医薬品サービス会社であるパレクセル・インターナショナル(PAREXEL International)(ナスダック:PRXL)は22日、米フロリダ州オーランドでの「第22回臨床試験における提携関係年次会議」で、新たな調査リポート「戦略的提携関係2013」を発表した。このリポートはアウトソーシングの現状と戦略的提携がすべての規模のバイオ医薬品会社に提供する価値を初めて探ったものである。戦略的提携はバイオ医薬品会社と臨床研究機関(CRO)(http://www.parexel.com/)の間の複数年の高度総合契約である。

同リポートで戦略的提携に関与し、インタビューを受けたバイオ医薬品業界の経営者85%が自社とCROとの関係は好影響を受けたと信じていることがわかった。経営者は臨床開発に対するより総合的なアプローチが自分の過失のレベルを下げ、固定コストを減少させ、内部では発見できなかった能力へのアクセスを提供すると信じている。

パレクセル・インターナショナルのジョセフ・フォン・リッケンバック役員会長兼最高経営責任者(CEO)は「戦略的提携関係2013はバイオ医薬品会社が円滑な統合、統一された目標、相互的な投資を通じて、より大きな価値を推進するために戦略的提携関係を結ぶことの重要性が増大していることを強調している。また同リポートは戦略的提携には、サイクル時間に対する追加的な共同集中、専門知識の共有、効率的な監視モデルを通じて生み出せるさらなる利点があることを示している」と語っている。

リポートのためにインタビューを受けた業界経営者は、戦略的提携が新たな療法を開発、商業化する手段を変革していると信じている。しかし、経営者は絶えず変化する規制環境の問題に適切、効果的に対応するようにモデルは変化しなければならないと指摘している。次世代の戦略的提携のビジョンについての質問には、商業的インセンティブの統一化、より深いチーム協力(戦略的および目標を定めた専門知識)、サイクル時間の改善による市場進出時間の短縮が上位3点に挙げられた。

今週開かれる「年次提携関係会議」(4月24日)で、フォン・リッケンバック会長は「2013年の医薬品の経済見通しに関するウォールストリート・リーダーシップ・パネルーアウトソーシング業界にとっての機会、投資領域、効果」というテーマのセッション/ラウンドテーブルでパネリストを務める。そのプレゼンテーションの一環として同会長はパレクセルの経験に基づく戦略的提携の利点と意味およびCRO(http://www.parexel.com/)業界の将来の見通しについて述べる。

▽「戦略的提携関係2013」について

中立系の調査会社であるブームズ・リサーチ&コンサルティング社はこのリポートのためにCスイート(経営幹部)のリーダーや臨床業務、研究開発、戦略的アウトソーシングの責任者など、世界的なバイオ医薬品会社を代表する上級レベルの経営者に突っ込んだインタビューを行った(n=26)。サンプルには71%の大規模医薬品会社、12%の中規模医薬品会社、17%の小規模医薬品会社が含まれている。インタビューは2012年秋に英語で行われた。参加者は合計で業界の研究開発支出の39%を占める企業を代表する。リポートには現在の臨床開発アウトソーシング(http://www.parexel.com/)と戦略的提携の状態をよりよく理解するために量的、質的問題が含まれている。このため一部の問題では合計が100%を超える。

リポート全文はhttp://www.parexel.comへ。

▽パレクセル・インターナショナル(PAREXEL International Corporation)について

パレクセル・インターナショナルは有力な世界的バイオ医薬品会社で、広い領域で知識ベースの委託研究、コンサルティング、医療コミュニケーション・サービスを世界の医薬品、バイオテクノロジー、医療機器業界に提供している。市場進出時間、ピーク・マーケット・ペネトレーションを促進するソリューションの提供にコミットしているパレクセルは、医薬品開発と規制コンサルティングから臨床薬理学、臨床試験管理、医療教育、償還に至る開発と商業化の連続体全体にわたって重要な専門知識を身につけている。パレクセルの子会社であるPerceptive Infomatics, Inc.は医療画像を含む先進的な技術ソリューションを提供して臨床開発プロセスを容易にしている。米マサチューセッツ州ボストン近くに本社を置くパレクセルは世界51カ国の73カ所で活動しており、従業員は約1万4000人。パレクセル・インターナショナルについての詳しい情報はhttp://www.parexel.comへ。

(C)2013 PAREXEL International Corporation。PAREXELはPAREXEL International Corporationの登録商標、Perceptive InfomaticsはPerceptive Infomatics, Inc.の登録商標。ほかのすべての名称、マークはPAREXEL International Corporation、Perceptive Infomatics, Inc.あるいはそれぞれの所有者の登録商標または商標であり、ここに通告する。

▽問い合わせ先

Diana Martin, Vice President

Corporate Communications

PAREXEL International

Tel: +1-781-434-5516

Email: Diana.Martin@PAREXEL.com

Katie Hepler

Ogilvy Public Relations

Tel: +1-212-880-5220

Email: Katie.Hepler@ogilvy.com;

Kim Leadley

PAN Communications

Tel: +1-617-502-4300

Email: PAREXEL@pancomm.com

ソース:PAREXEL International

New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry

PR52787

BOSTON, Apr. 22, 2013 /PRN=KYODO JBN/ --

   Majority of biopharma executives believe Strategic Partnerships positively

                impact their engagement with CROs

    PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical

services organization, today released a new research report called Strategic

Partnerships 2013 at the 22nd Annual Partnerships in Clinical Trials Conference

in Orlando, FL. The report is the first to explore the current outsourcing

landscape and the value Strategic Partnerships provide to biopharmaceutical

companies of all sizes. Strategic Partnerships are multi-year,

highly-integrated engagements between biopharmaceutical companies and clinical

research organizations (http://www.parexel.com/ )(CROs).

    The report found that 85% of biopharmaceutical industry executives

interviewed and who were engaged in Strategic Partnerships, believe that the

relationship between their companies and CROs were positively impacted.

Executives believe this more integrated approach to clinical development

reduces their level of oversight, decreases fixed costs and provides them with

access to capabilities not found internally.

    "Strategic Partnerships 2013 highlights the growing importance to

biopharmaceutical companies of engaging in Strategic Partnerships to drive

greater value through seamless integration, aligned goals and mutual

investment," said Josef von Rickenbach, Chairman of the Board and Chief

Executive Officer of PAREXEL International. "The report also illustrates that

there are further benefits of Strategic Partnerships that can be generated

through additional joint focus on cycle times, shared expertise and efficient

oversight models."

    The industry executives interviewed for this report believe Strategic

Partnerships are transforming the way new therapies are developed and

commercialized. However, they also noted that the model must evolve to

adequately and effectively meet the challenges of a constantly changing

regulatory environment. When asked about the vision for the next-generation of

Strategic Partnerships, the respondents identified increased alignment in

commercial incentives, deeper team collaboration (strategic and targeted

expertise) and faster time-to-market through improved cycle times as the top

three areas.

    Later this week at the Annual Partnerships conference (Wednesday, April

24), Mr. von Rickenbach will serve as a panelist at a session/roundtable

titled, "Wall Street Leadership Panel on the Economic Outlook for Pharma in

2013 - Opportunities, Investment Areas and Effects on the Outsourcing

Industry." As part of his presentation, he will discuss the benefits and

implications of Strategic Partnerships based on PAREXEL's experience, and the

CRO (http://www.parexel.com/ ) industry's future outlook.

    About Strategic Partnerships 2013

    For the report, Booms Research & Consulting, Inc. - an independent research

firm conducted in-depth interviews among senior-level executives such as

C-suite leaders as well as heads of clinical operations, R&D, and strategic

outsourcing, representing global biopharmaceutical companies (n=26). The sample

size included: 71% large pharmaceutical companies, 12% mid-sized pharmaceutical

companies, and 17% small biopharmaceutical companies. The interviews were

conducted in English in the fall 2012. Participants represent companies with

39% of industry R&D spend. The report included both quantitative and

qualitative questions to better understand the current state of clinical

development outsourcing (http://www.parexel.com/ ) and strategic partnerships.

The survey includes both single and multiple response questions. As such, some

percentages will exceed 100%.

    For a full copy of the report, please visit: http://www.parexel.com

    About PAREXEL International

    PAREXEL International Corporation is a leading global biopharmaceutical

services organization, providing a broad range of knowledge-based contract

research, consulting, and medical communications services to the worldwide

pharmaceutical, biotechnology and medical device industries. Committed to

providing solutions that expedite time-to-market and peak-market penetration,

PAREXEL has developed significant expertise across the development and

commercialization continuum, from drug development and regulatory consulting to

clinical pharmacology, clinical trials management, medical education and

reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides

advanced technology solutions, including medical imaging, to facilitate the

clinical development process. Headquartered near Boston, Massachusetts, PAREXEL

operates in 73 locations throughout 51 countries around the world, and has

approximately 14,000 employees. For more information about PAREXEL

International visit http://www.parexel.com.

    This release contains "forward-looking" statements regarding future results

and events. For this purpose, any statements contained herein that are not

statements of historical fact may be deemed forward-looking statements. Without

limiting the foregoing, the words "believes," "anticipates," "plans,"

"expects," "intends," "appears," "estimates," "projects," "will," "would,"

"could," "should," "targets," and similar expressions are also intended to

identify forward-looking statements. The forward-looking statements in this

release involve a number of risks and uncertainties. The Company's actual

future results may differ significantly from the results discussed in the

forward-looking statements contained in this release. Important factors that

might cause such a difference include, but are not limited to, risks associated

with: actual operating performance; actual expense savings and other operating

improvements resulting from recent and anticipated restructurings; the loss,

modification, or delay of contracts which would, among other things, adversely

impact the Company's recognition of revenue included in backlog; the Company's

dependence on certain industries and clients; the Company's ability to win new

business, manage growth and costs, and attract and retain employees; the

Company's ability to complete additional acquisitions and to integrate newly

acquired businesses or enter into new lines of business; the impact on the

Company's business of government regulation of the drug, medical device and

biotechnology industry; consolidation within the pharmaceutical industry and

competition within the biopharmaceutical services industry; the potential for

significant liability to clients and third parties; the potential adverse

impact of health care reform; and the effects of exchange rate fluctuations and

other international economic, political, and other risks. Such factors and

others are discussed more fully in the section entitled "Risk Factors" of the

Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December

31, 2012 as filed with the SEC on February 1, 2013, which "Risk Factors"

discussion is incorporated by reference in this press release. The Company

specifically disclaims any obligation to update these forward-looking

statements in the future. These forward-looking statements should not be relied

upon as representing the Company's estimates or views as of any date subsequent

to the date of this press release.

    (C) 2013 PAREXEL International Corporation. PAREXEL is a registered

trademark of PAREXEL International Corporation, and Perceptive Informatics is a

registered trademark of Perceptive Informatics, Inc. All other names or marks

may be registered trademarks or trademarks of PAREXEL International

Corporation, Perceptive Informatics, Inc. or their respective owners and are

hereby acknowledged.

    CONTACT: Diana Martin, Vice President           

             Corporate Communications               

             PAREXEL International                  

             Tel: +1-781-434-5516                   

             Email: Diana.Martin@PAREXEL.com;

             Katie Hepler

             Ogilvy Public Relations

             Tel: +1-212-880-5220

             Email: Katie.Hepler@ogilvy.com;

      

             Kim Leadley

             PAN Communications

             Tel: +1-617-502-4300

             Email: PAREXEL@pancomm.com

     SOURCE: PAREXEL International

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中